24.10.2017

NARMS report, main point:
- For retail chicken meat testing in 2015, Salmonella recovery continued to decline to the lowestl evels in 14 years of NARMS retail meat testing, ,falling to 6.1% in 2015. A parallel decline occurred in retail ground turkey. Similarly, the occurrence of Campylobacter in retail chicken samples has declined steadily, down from a peak of 60% in 2004 to 24% in 2015.
- In 2015, 76% of Salmonella isolated from humans had no resistance to any of  the antimicrobial drugs tested.
- Multidrug resistance (MDR) increased from 9 percent to 12 percent of human Salmonella, driven largely by an increase in combined resistance to ampicillin, streptomycin, sulfonamides, and tetracycline among Salmonella serotype I 4,[5],12:i:-.
- Erythromycin resistance in Campylobacter coli increased three-to five-fold between 2011 and 2015 in isolates from humans (2.7 percent to 12.7 percent) and from chicken carcasses (3.4 percent to 12.8 percent).
- Transmissible quinolone resistance in Salmonella may be increasing. The underlying resistance traits reside on mobile genetic elements and therefore have the potential to be shared, either alone or together with other resistance genes, with susceptible strains of Salmonella.
Fluoroquinolones are an alternative therapy for treating campylobacteriosis in adults. Fluoroquinolones have not been used in chickens and turkeys since 2005. Ciprofloxacin resistance increased in Campylobacter coli from humans and continued to increase or remained high in Campylobacter jejuni isolates from cattle and chicken.
- From 2014 to 2015, there was a decline from 73 percent to 57 percent in the proportion of retail ground turkey Salmonella isolates resistant to at least one antimicrobial. Historically, the majority of isolates from turkey sources have been resistant to at least one antimicrobial.